

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ :

C07D 277/10, A61K 31/425

A1

(11) International Publication Number:

WO 97/36885

(43) International Publication Date:

9 October 1997 (09.10.97)

(2i) International Application Number: PCT/US97/04666

(22) International Filing Date: 31 March 1997 (31.03.97)

(30) Priority Data:

08/624,289

29 March 1996 (29.03.96)

US

(71) Applicant: UNIVERSITY OF FLORIDA [US/US]; 186 Grinter Hall, Gainesville, FL 32611-2037 (US).

(72) Inventor: BERGERON, Raymond, J., Jr.; 6220 N.W. 56th Lane, Gainesville, FL 32604 (US).

(74) Agent: CLARKE, Dennis, P.; Kerkam, Stowell, Kondracki & Clarke, P.C., Suite 600, Two Skyline Place, 5203 Leesburg Pike, Falls Church, VA 22041-3401 (US).

(81) Designated States: AU, BB, BG, BR, CA, CZ, HU, JP, KP, KR, LK, LV, MG, MN, NO, NZ, PL, RO, SK, UA, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

*With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: THIAZOLINE ACID DERIVATIVES

(57) Abstract

2-(2-Hydroxy aryl)-thiazoline-4-carboxylic acids and derivatives are useful as chelators of trivalent metals in therapeutic applications.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶:**C07D 277/10, A61K 31/425****A1**

(11) International Publication Number:

WO 97/368

(43) International Publication Date:

9 October 1997 (09.10.)

(21) International Application Number: **PCT/US97/04666**(22) International Filing Date: **31 March 1997 (31.03.97)**

(30) Priority Data:

08/624,289**29 March 1996 (29.03.96)****US**(71) Applicant: **UNIVERSITY OF FLORIDA [US/US]; 186 Grinter Hall, Gainesville, FL 32611-2037 (US).**(72) Inventor: **BERGERON, Raymond, J., Jr.; 6220 N.W. 56th Lane, Gainesville, FL 32604 (US).**(74) Agent: **CLARKE, Dennis, P.; Kerkam, Stowell, Kondracki & Clarke, P.C., Suite 600, Two Skyline Place, 5203 Leesburg Pike, Falls Church, VA 22041-3401 (US).**(81) Designated States: **AU, BB, BG, BR, CA, CZ, HU, JP, KR, LK, LV, MG, MN, NO, NZ, PL, RO, SK, UA, UZ, V**
ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Euras
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Europe
patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE,
LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, I
CM, GA, GN, ML, MR, NE, SN, TD, TG).**Published***With international search report.**Before the expiration of the time limit for amending i
claims and to be republished in the event of the receipt
amendments.*(54) Title: **THIAZOLINE ACID DERIVATIVES**

(57) Abstract

2-(2-Hydroxy aryl)-thiazoline-4-carboxylic acids and derivatives are useful as chelators of trivalent metals in therapeutic application.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroun			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

THIAZOLINE ACID DERIVATIVES**BACKGROUND OF THE INVENTION**

Research leading to the completion of the invention was supported in part by Grant Nos. 3203522-12, RO1HL42817 and RO1DK49108 awarded by the National Institutes of Health (NIH).

5 The United States Government has certain rights in and to the claimed invention.

Field of the Invention

The present invention relates to novel thiazoline acids and derivatives thereof useful as chelators of trivalent
10 metals in therapeutic applications.

Discussion of the Prior Art

While many organisms are auxotrophic for Fe (III), because of the insolubility of the hydroxide ($K_{sp} = 1 \times 10^{-38}$) [Acc. Chem. Res., Vol. 12, Raymond et al, "Coordination Chem-
15 istry and Microbial Iron Transport," pages 183-190 (1979)] formed under physiological conditions, nature has developed rather sophisticated iron storage and transport systems. Microorganisms utilize low molecular weight ligands, siderophores, while eukaryotes tend to utilize proteins to transport
20 iron, e.g., transferrin, and store iron, e.g., ferritin [Trends in Biochem. Sci., Vol. 11, Bergeron, "Iron: A Controlling Nutrient in Proliferative Processes," pages 133-136 (1986)].

Iron metabolism in primates is characterized by a highly efficient recycling process with no specific mechanism for eliminating this transition metal [Clin. Physiol. Biochem., Vol. 4, Finch et al, "Iron Metabolism," pages 5-10 (1986); Ann. Rev. Nutri., Vol. 1, Hallberg, "Bioavailability of Dietary Iron in Man," pages 123-147 (1981); N. Engl. J. Med., Vol. 306, Finch et al, "Perspectives in Iron Metabolism," pages 1520-1528 (1982); and Medicine (Baltimore), Vol. 49, Finch et al, "Ferrokinetics in Man," pages 17-53 (1970)].

Because it cannot be effectively cleared, the introduction of "excess iron" into this closed metabolic loop leads to chronic overload and ultimately to peroxidative tissue damage [The Molecular Basis of Blood Diseases, Seligman et al, "Molecular Mechanisms of Iron Metabolism," page 219 (1987); Biochem. J., Vol. 229, O'Connell et al, "The Role of Iron in Ferritin- and Haemosiderin-Mediated Lipid Peroxidation in Liposomes," pages 135-139 (1985); and J. Biol. Chem., Vol. 260, Thomas et al, "Ferritin and Superoxide-Dependent Lipid Peroxidation," pages 3275-3280 (1985)]. There are a number of scenarios which can account for "iron overload," e.g., high-iron diet, acute iron ingestion or malabsorption of the metal. In each of these situations, the patient can be treated by phlebotomy [Med. Clin. N. Am., Vol. 50, Weintraub et al, "The Treatment of Hemochromatosis by Phlebotomy," pages 1579-1590 (1966)]. However, there are iron-overload syndromes secondary to chronic transfusion therapy, e.g., aplastic anemia and thalassemia in which phlebotomy is not an option [Iron in Biochemistry and

Medicine, Vol. II, Hoffbrand, "Transfusion Siderosis and Chelation Therapy," page 499 (London, 1980)]. The patient cannot be bled, as the origin of the excess iron is the transfused red blood cells; thus, the only alternative is chelation therapy. However, to be therapeutically effective, a chelator must be able to remove a minimum of between 0.25 and 0.40 mg of Fe/kg per day [Semin. Hematol., Vol. 27, Brittenham, "Pyridoxal Isonicotinoyl Hydrazone: An Effective Iron-Chelator After Oral Administration," pages 112-116 (1990)].

Although considerable effort has been invested in the development of new therapeutics for managing thalassemia, the subcutaneous (sc) infusion of desferrioxamine B, a hexa-coordinate hydroxamate iron chelator produced by Streptomyces pilosus [Helv. Chim. Acta, Vol. 43, Bickel et al, "Metabolic Properties of Actinomycetes. Ferrioxamine B," pages 2129-2138 (1960)], is still the protocol of choice. Although the drug's efficacy and long-term tolerability are well-documented, it suffers from a number of shortcomings associated with low efficiency and marginal oral activity.

Although a substantial number of synthetic iron chelators have been studied in recent years as potential orally active therapeutics, e.g., pyridoxyl isonicotinoyl hydrazone (PIH) [FEBS Lett., Vol. 97, Ponka et al, "Mobilization of Iron from Reticulocytes: Identification of Pyridoxal Isonicotinoyl Hydrazone as a New Iron Chelating Agent," pages 317-321 (1979)], hydroxypyridones [J. Med. Chem., Vol. 36,

Uhlir et al, "Specific Sequestering Agents for the Actinides.
21. Synthesis and Initial Biological Testing of Octadentate
Mixed Catecholate-hydroxypyridinonate Ligands," pages 504-509
(1993); and Lancet, Vol. 1, Kontoghiorghe et al, "1,2-
5 Dimethyl-3-hydroxypyrid-4-one, an Orally Active Chelator for
the Treatment of Iron Overload," pages 1294-1295 (1987) and
bis(o-hydroxybenzyl)-ethylenediaminediacetic acid (HBED)
analogues [Ann. N.Y. Acad. Sci., Vol. 612, Grady et al, "HBED:
A Potential Oral Iron Chelator," pages 361-368 (1990)], none
10 has yet proven to be completely satisfactory. Interestingly,
the siderophores have remained relatively untouched in this
search. Their evaluation as iron-clearing agents has not at
all paralleled the rate of their isolation and structural
elucidation. In fact, until recently, beyond DFO, only two of
15 some 100 siderophores identified have been studied in animal
models: enterobactin [Gen. Pharmac., Vol. 9, Guterman et al,
"Feasibility of Enterochelin as an Iron-Chelating Drug:
Studies with Human Serum and a Mouse Model System," pages
123-127 (1978)] and rhodotorulic acid [J. Pharmacol. Exp.
20 Ther., Vol. 209, Grady et al, "Rhodotorulic Acid-Investigation
of its Potential as an Iron-Chelating Drug," pages 342-348
(1979)]. While the former was only marginally effective at
clearing iron, the latter compound was reasonably active.
Unfortunately, both of these cyclic siderophores exhibited
25 unacceptable toxicity, and neither possessed any oral
activity. They were abandoned as there were any number of

synthetic chelators with equally unsatisfactory properties from which to choose.




U.S. Patent No. 4,406,905 and Bergeron et al, J. Med. Chem., Vol. 34, No. 7, pages 2072-2078 (1991), the entire contents and disclosures of both of which are incorporated herein by reference, disclose that desferrithiocin and certain 2-pyridyl-2-thiazoline-4-carboxylic acids and derivatives thereof are useful in the treatment of iron overload conditions.


It is an object of the present invention to provide novel thiazoline acids and derivatives thereof which, because of different volumes of distribution in patients and different lipophilicities than the derivatives of the prior art, provide the ability to control the pharmacokinetic properties and toxicities of the drugs.

Another object of the present invention is to provide novel pharmaceutical compositions for and methods of treatment of human and non-human animals in need of therapy entailing the prevention of deposition of trivalent metals and compounds thereof in tissues thereof, as well as the elimination of such metals and compounds from systems overloaded therewith.


SUMMARY OF THE INVENTION

The above and other objects are realized by the present invention, one embodiment of which relates to compounds of the formulae:






(IV),



(V),




(VI)

wherein: R may be H or acyl, e.g., acetyl, propionyl, butyryl, benzoyl, and the like;

R_1, R_2, R_3, R_4 and R_7 may be the same or different and represent H, alkyl or hydrocarbyl arylalkyl having up to 14 carbon atoms, or $-\text{CH}_2[\text{O}-(\text{CH}_2)_x]_y\text{OCH}_3$, wherein x is 1-10 and y is 0-10;

5 R_5 is H, alkyl or hydrocarbyl aralkyl having up to 15 carbon atoms, $-\text{CH}_2)_{1-2}[\text{O}(\text{CH}_2)_x]_y\text{OCH}_3$, wherein x is 1-10 and y is 0-10, or



defined above, z is 1-10 and q is 0-5;

10 R_6 is H or acyl, as above;

n is 0-10;


a salt thereof with a pharmaceutically acceptable acid, or a pharmaceutically acceptable complex thereof.

15 A further embodiment of the invention comprises a pharmaceutical composition in unit dosage form comprising a therapeutically effective amount of the above compound and a pharmaceutically acceptable carrier therefor.


20 An additional embodiment of the invention concerns a method of preventing or treating a pathological condition in a human or non-human animal that is associated with an excess

of a trivalent metal, ion or compound thereof comprising administering to the animal a therapeutically effective amount of the above compound.




Another embodiment of the invention relates to compounds of the formulae:




(VII),



(VIII),





wherein: R may be H or acyl, e.g., acetyl, propionyl, butyryl, benzoyl, and the like;

R_1 , R_2 , R_3 , R_4 and R_7 may be the same or different and represent H, alkyl or hydrocarbyl arylalkyl having up to 14 carbon atoms, or $-\text{CH}_2[\text{O}-(\text{CH}_2)_x]_y\text{OCH}_3$;

x is 1-10; and


y is 0-10;

or a pharmaceutically acceptable salt or complex thereof.


DETAILED DESCRIPTION OF THE INVENTION

The present invention is predicated on the discovery that compounds of the above formulae I-XII are valuable bio-active chelators or sequestrants for trivalent metals such as Fe, Al and Cr. They can be administered to human and non-human mammals to prevent the deposition of, e.g., iron in the tissues thereof. They are also useful for the elimination of, e.g., iron from such mammals afflicted with, e.g., haemochromatosis, haemosiderosis and also cirrhosis. They also find application in dialysis, encephalopathy, osteomalacia and Alzheimer's disease.

The compounds of formulae I-XII are characterized by the asymmetric carbon atom marked with an asterisk (*). The bonds surrounding these carbon atoms are arranged tetrahedrally and the substituents thus bonded to the asymmetric carbon atoms are in fixed positions. The compounds of formulae I-XII represent optical antipodes exhibiting either the (S) or (R) conformation as shown in (i) and (ii) below:



(S) conformation




(R) conformation

In the above formulae I-XII, R is preferably H, but may also be a suitable acyl group which is cleavable under physiological conditions to the free hydroxyl compounds and a biologically acceptable acid. Such acyl groups are known in the art, e.g., the acyl radical of a carbonic acid semiester, in particular carbonic acid semi-C₁-C₄-alkyl ester or carbonic acid semi-oxaalkyl ester in which oxaalkyl has 4-13 chain members such as an acyl radical -C(=O)-(O-CH₂-CH₂)_n-O-Alk in which n is an integer from 0 to 4 and Alk represents C₁-C₄ alkyl, in particular methyl or ethyl. Such acyl groups are, for example, methoxycarbonyl, ethoxycarbonyl or 2-(methoxyethoxy)-ethoxycarbonyl. Further acyl radicals are, for example, C₁-C₃-alkanoyl such as acetyl or propionyl, or mono-substituted or di-substituted carbamoyl such as di-C₁-C₄-alkyl carbamoyl, for example, dimethylcarbamoyl or diethylcarbamoyl, or C₁-C₄-alkoxycarbonyl-C₁-C₄-alkylcarbamoyl, for example, methoxycarbonylmethylcarbamoyl, ethoxycarbonylmethylcarbamoyl or 2-ethoxycarbonylethylcarbamoyl.

R₁, R₂, R₃, R₄ and R₇ may be H, straight or branched chain alkyl having up to 14 carbon atoms, e.g., methyl, ethyl, propyl and butyl; arylalkyl wherein the aryl portion is hydrocarbyl and the alkyl portion is straight or branched chain, the arylalkyl group having up to 14 carbon atoms, or -CH₂[O-(CH₂)_x]_yCH₃ wherein x is 1-10 and y is 0-10.

R₅ is preferably straight or branched chain alkyl having up to 15 carbon atoms, but may also be H;

-(CH₂)₁₋₂[O-(CH₂)_x]_yOCH₃, wherein x is 1-10 and y is 0-10;



z is 1-10 and q is 0-5.

R_6 is preferably H, but may also be acyl as described above.

5 Exemplary of the compounds of formulae I-XII are
 (S)-desmethyldesferrithiocin, N-methylhydroxamate;
 (S)-desmethyldesferrithiocin, N-[5-(acetylhydroxyamino)-
 pentyl]hydroxamate; 2-(2'-hydroxynaphth-1'-yl)- Δ^2 -thiazoline-
 (4R)-carboxylic acid; 2-(2'-hydroxynaphth-1'-yl)- Δ^2 -
 10 thiazoline-(4S)-carboxylic acid; 2-(3'-hydroxynaphth-2'-yl)-
 Δ^2 -thiazoline-(4R)-carboxylic acid; and 2-(3'-hydroxynaphth-
 2'-yl)- Δ^2 -thiazoline-(4S)-carboxylic acid.

It will be understood that salts of the compounds of
 formulae I-VI with pharmaceutically acceptable acids also com-
 15 prise part of the present invention. Suitable such acids
 include hydrochloric, sulfuric or phosphoric acids, as well as
 methanesulfonic, arginine, lysine, and the like.


The invention also includes pharmaceutically accept-
 able salts of the carboxylic acids of formulae VII-XII. Thus,
 20 ammonium salts and metal salts such as the alkali metal and
 alkaline earth metals salts, e.g., sodium, potassium, mag-
 nesium or calcium salts, as well as divalent metal salts such
 as zinc, and salts with suitable organic amines, there coming

into consideration such salt formation especially aliphatic, cycloaliphatic, cycloaliphatic-aliphatic or araliphatic primary, secondary or tertiary mono-, di- or poly-amines, and also heterocyclic bases. Such amines are, for example, lower alkylamines, for example, triethylamine, hydroxy-lower alkylamines, for example, 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tris-(2-hydroxyethyl)-amine, basic aliphatic esters of carboxylic acids, for example, 4-aminobenzoic acid 2-diethylaminoethyl ester, lower alkyleneamines, for example, 1-ethylpiperidine, cycloalkylamines, for example, dicyclohexylamine, or benzylamines, for example, N,N'-dibenzylethylenediamine, also bases of the pyridine type, for example, pyridine, collidine or quinoline. Further salts include internal salts (zwitterionic forms of compounds of the invention), wherein a basic group, for example, the basic nitrogen atom present in the pyridine ring, is protonated by a hydrogen ion originating from an acid group in the molecule.

Owing to their high solubility and good tolerability, metal ion complexes of compounds of the above formulae, especially with suitable paramagnetic and/or radioactive metals, can be used as contrast agents in diagnostic medicine, for example, X-ray, radionuclide, ultrasound and/or magnetic resonance diagnostics.


Compounds of formulae I and II may be synthesized by reacting:

- a. a picolinic acid derivative of the formula



in which R and R₄ are as defined above and Y represents carboxy or a reactive functional derivative of a carboxy group, with

- b. a reactive cysteine derivative of the formula



wherein hydroxy groups are optionally protected to produce a compound of formula I or II after splitting off optionally present protective groups and, optionally, conversion to a suitable salt.

Free hydroxy groups present in the compounds of the above formulae are optionally protected by conventional protecting groups. Such protecting groups protect the hydroxy groups from undesired condensation reactions, substitution reactions and the like. The protecting groups can be introduced and removed easily, i.e., without undesirable secondary reactions taking place, for example, by solvolysis or reduction, in a manner known per se. Protecting groups and the methods by which they are introduced and split off are described, for example, in "Protective Groups in Organic Chemistry," Plenum Press, London, New York (1973) and also in "Methoden der organischen Chemie," Houben-Weyl, 4th edition, Vol. 15/1, Georg Thieme Verlag, Stuttgart (1974).

Suitable hydroxy-protecting groups are, for example, acyl radicals such as lower alkanoyl optionally substituted, for example, by halogen such as 2,2-dichloroacetyl, or acyl radicals of carbonic acid semiesters, especially tert.-butoxycarbonyl, optionally substituted benzyloxycarbonyl, for example, 4-nitrobenzyloxycarbonyl, or diphenylmethoxycarbonyl, alkenyloxycarbonyl, for example, allyloxycarbonyl, or 2-halo-lower alkoxycarbonyl such as 2,2,2-trichloroethoxycarbonyl, also trityl or formyl, or organic silyl radicals, also etherifying groups that can readily be split off such as tert.-lower alkyl, for example, tert.-butyl, or 2-oxa- or 2-thia-cycloalkyl having 5 or 6 ring atoms, for example, tetrahydrofuryl or 2-tetrahydropyranyl or corresponding thia analogues, and also optionally substituted 1-phenyl-lower

alkyl such as optionally substituted benzyl or diphenylmethyl, there coming into consideration as substituents of the phenyl radicals, for example, halogen such as chlorine, lower alkoxy such as methoxy, and/or nitro.

5 A reactive functional derivative of a carboxy group (Y) is, for example, an acid anhydride, an activated ester or an activated amide, cyano, a group of the formula $-C(OR)_3$, or $-C(=NH)-R_0$ in which R_0 is lower alkyl. Corresponding derivatives are well known in the art.

10 Of the anhydrides, the mixed anhydrides are especially suitable. Mixed anhydrides are, for example, those with inorganic acids such as hydrohalic acids, i.e., the corresponding acid halides, for example, chlorides or bromides, also with hydrazoic acid, i.e., the corresponding acid azides.

15 Further mixed anhydrides are, for example, those with organic carboxylic acids such as with lower alkanecarboxylic acids optionally substituted, for example, by halogen such as fluorine or chlorine, for example, pivalic acid or trichloroacetic acid, or with semiesters, especially lower alkyl semi-

20 esters of carbonic acid such as the ethyl or isobutyl semi-ester of carbonic acid, or with organic, especially aliphatic or aromatic, sulfonic acids, for example, p-toluenesulfonic acid. Of the activated esters, there may be mentioned, for

25 example, esters with vinylogous alcohols (i.e., enols such as vinylogous lower alkenols), or iminomethyl ester halides such

as dimethyliminomethyl ester chloride (prepared from the carboxylic acid and, for example, dimethyl-(1-chloroethylidene)-iminium chloride of the formula $(\text{CH}_3)_2\text{N}^+=\text{C}(\text{Cl})\text{CH}_2\text{Cl}^-$, which can be obtained, for example, from N,N-dimethylacetamide and phosgene), or aryl esters such as preferably suitable substituted phenyl esters, for example, phenyl ester substituted by halogen such as chlorine, and/or by nitro, for example, 4-nitrophenyl ester, 2,3-dinitrophenyl ester or 2,3,4,5,6-pentachlorophenyl ester, N-hetero-aromatic esters such as N-benzotriazole esters, for example, 1-benzotriazole ester, or N-diacylimino esters such as N-succinylamino or N-phthalyl-imino ester. Suitable activated amides are, for example, imidazolides, also 1,2,4-triazolides, tetrazolides or 1,2,4-oxadiazolinonides.

The activation of the carboxy group Y in the compounds of the above formulae can also be effected in situ.

A reactive functional derivative of a cysteine of the above formulae is a compound in which the amino and/or mercapto group is activated for the reaction with the carboxy group of a compound of the above formulae, that is to say, is present in nucleophilic form. The amino group is activated, for example, by reaction with a phosphite.


The reaction of the above compounds in which Y represents carboxy with the cysteine derivative is preferably carried out in the presence of a suitable condensation agent or under dehydrating conditions, for example, while removing the water of reaction by azeotropic distillation. Customary

condensation agents are, for example, carbodiimides, for example, N,N'-diethyl-, N,N'-dipropyl-, N,N'-dicyclohexyl- or N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide, suitable carbonyl compounds, for example, carbonyldiimidazole, or 1,2-oxazolium compounds, for example, 2-ethyl-5-phenyl-1,2-oxazolium-3'-sulfonate or 2-tert.-butyl-5-methyl-isoxazolium perchlorate, for a suitable acylamino compound, for example, 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, furthermore diphenylphosphoryl azide. The condensation reaction is carried out preferably in an anhydrous reaction medium, preferably in the presence of a solvent or diluent, for example, methylene chloride, benzene or tetrahydrofuran and, if necessary, while cooling or heating, for example, at ambient temperature or at slightly elevated temperature, and/or in an inert gas atmosphere. If a compound in which Y represents an acid anhydride derivative of a carboxy group is carried out, the reaction is performed under essentially the same conditions in the presence of a basic agent such as the sodium or potassium salt or carbonic acid, or a tertiary amino compound such as a tri-C₁-C₄-alkyl amine, for example, triethylamine, or a pyridine base such as pyridine or quinoline.


A preferred form of this process according to the invention is the reaction of a compound of the above formulae in which Y represents cyano with a cysteine derivative of the above formulae. The reaction is carried out in an inert solvent such as an aqueous solvent at ambient temperature or, preferably, at slightly elevated temperature, for example, at


about 50° to 80°C, and preferably under an inert gas atmosphere.

It is also possible to carry out the above-described process wherein the cysteine derivative is of the formula:



wherein R_1 , R_2 and R_3 are as described above and Z is carboxy or a reactive functional derivative thereof, for example, an activated ester to produce a compound of the formula:





followed by reaction with a compound of the formula $\text{H}-\text{N}-\text{R}_5$
 OR_6

or with a compound which is convertible thereto. A preferred functional derivative of a carboxy group according to the invention is the N-succinylimino ester. The reaction is performed in an inert solvent such as an aprotic solvent, for example, dimethylformamide, dimethylsulfoxide or dioxane or a C₁-C₄ alkanol such as methanol, at ambient temperature or while cooling, for example, at about 0°C.

In resulting compounds in which one or more functional (hydroxy) groups are protected, the latter can be freed, optionally in stages or simultaneously, in a manner known per se, by means of solvolysis, especially hydrolysis or acidolysis, or in some cases also by means of careful reduction. Silyl protecting groups are advantageously split off with fluorides, for example, tetraethylammonium fluoride.

Compounds of formulae III-XII are prepared by methods differing from those described above since cysteine reacts poorly with 2-hydroxy-1-naphthonitrile. The syntheses of the naphthyl derivatives is dependent on accessing the intermediate imidate. Thus, e.g., ethyl-2-hydroxy-1-naphth-imidate is assembled in six steps starting from 2-hydroxy-1-naphthaldehyde. The hydroxyl of aldehyde is alkylated (benzyl chloride/K₂CO₃, EtOH, reflux, 39 hours), providing the benzyl

ether. The aldehyd function is oxidized to the acid with NaClO_2 and sulfamic acid in aqueous acetone at 0°C for 50 minutes. Conversion to the acid chloride (oxalyl chloride/toluene/DMF, 25°C , 1 hour) and treatment with concentrated $\text{NH}_4\text{OH}/\text{CH}_2\text{Cl}_2$ at room temperature for one day yields the amide. The amide is smoothly converted to the ethyl imidate with Meerwein's salt ($\text{Et}_3\text{O}^+\text{PF}_6^-/\text{CH}_2\text{Cl}_2$) for one day at room temperature. The benzyl protecting group is removed by hydrogenolysis (Pd-C/ethanol) to yield the key intermediate. Cyclocondensation thereof with L- or D-cysteine in refluxing methanol for two days generates the iron chelators, as the free acid.

The starting material for the synthesis of the naphthyl DFTs is 3-hydroxy-2-naphthoic acid. The hydroxyl group is acylated with acetic anhydride (concentrated H_2SO_4 , reflux, 5 minutes). The resulting acid is converted to the corresponding acid chloride (oxalyl chloride/toluene/DMF, 25°C , 1 hour); reaction with concentrated NH_4OH (CH_2Cl_2 , 25°C , 24 hours) results in the ester-cleaved amide. The free hydroxyl is re-acetylated (Ac_2O /pyridine, 25°C , 30 minutes). Dehydration of the amide and concomitant cleavage of the acetyl group using SOCl_2 at reflux for 2 hours furnishes the key nitrile intermediate. It undergoes cyclization with either L- or D-cysteine (methanolic 0.1 M phosphate buffer, pH 5.95, 60°C , 1-2 days) to provide the naphthyl chelators.

Salts of compounds of the invention can be manufactured in a manner known per se. Thus, salts of compounds having acidic groups can be formed, for example, by treating with metal compounds such as alkali metals salts of suitable organic carboxylic acids, for example, the sodium salt of α -ethylcaproic acid, or with inorganic alkali metal or alkaline earth metal salts, for example, sodium bicarbonate, or with ammonia or a suitable organic amine, preferably stoichiometric quantities or only a small excess of the salt-forming agent being used. Acid addition salts of compounds of the invention are obtained in a customary manner, for example, by treating with an acid or a suitable anion-exchange reagent. Internal salts of compounds of the invention (zwitterionic forms) can be formed, for example, by neutralizing the compounds or salts such as acid addition salts, to the isoelectric point, for example, with weak bases, or by treating with liquid ion exchangers.

Salts can be converted in a customary manner into the free compounds: metal and ammonium salts can be converted into the free compounds, for example, by treating with suitable acids, and acid addition salts, for example, by treating with a suitable basic agent.

The starting materials are available commercially and/or known or can be manufactured by known processes.

The racemate can be split in a manner known per se, for example, after conversion of the optical antipodes into diastereoisomers, for example, by reaction with optically active acids or bases.

5 The pharmacologically acceptable compounds of the present invention can be used, for example, for the manufacture of pharmaceutical compositions which contain an effective amount of the active substance together or in admixture with inorganic or organic, solid or liquid, pharmaceutically
10 acceptable carriers.

 The pharmaceutical compositions according to the invention are those which are suitable for enteral, such as oral, administration and for parenteral, such as subcutaneous, administration to warm-blooded animals, especially humans, and
15 which contain the pharmacological active substance on its own or together with a pharmaceutically acceptable carrier. The dosage of the active substance depends on the species of warm-blooded animal and on the age and individual condition, the illness to be treated and also on the mode of administration.

20 The novel pharmaceutical preparations contain from approximately 10% to approximately 95%, and preferably from approximately 20% to approximately 90%, of the active substance. Pharmaceutical compositions according to the invention can, for example, be in unit dose form, such as dragées,
25 tablets, capsules, suppositories or ampoules, and contain from approximately 0.1 g to approximately 3.0 g, and preferably

from approximately 0.3 g to approximately 1.0 g, of the active ingredient.

5 The pharmaceutical compositions of the present invention are manufactured in a manner known per se, for example, by means of conventional mixing, granulating, confectioning, dissolving or lyophilizing processes. Pharmaceutical compositions for oral use can be obtained by combining the active substance with one or more solid carriers, if desired, granulating a resulting mixture and processing the
10 mixture or granulate, if desired or necessary after the addition of suitable adjuncts, to form tablets or dragée cores. In so doing, they can also be incorporated into plastics carriers which release the active substances or allow them to diffuse in controlled amounts.

15 Suitable carriers are especially fillers such as guars, for example, lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example, tricalcium phosphate or calcium hydrogen phosphate, also binders such as starches, for example, corn, wheat, rice or
20 potato starch, gelatine, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and/or, if desired, disintegrators such as the above-mentioned starches, also carboxymethyl starch, cross-linked polyvinylpyrrolidone, agar, alginic acid or a
25 salt thereof such as sodium alginate. Adjuncts are especially

flow-regulating and lubricating agents, for example, silica, talc, stearic acid or salts thereof such as magnesium or calcium stearate, and/or polyethylene glycol. Dragée cores are provided with suitable coatings that are, if desired, resistant to gastric juice, there being used, inter alia, concentrated sugar solutions which optionally contain gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions in suitable organic solvents or solvent mixtures or, for the manufacture of coatings that are resistant to gastric juice, solutions of suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Coloring substances or pigments can be added to the tablets or dragée coatings, for example, for the purpose of identification or for indicating different doses of active substance.

Other orally administrable pharmaceutical compositions are dry-filled capsules made of gelatin and also soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The dry-filled capsules may contain the active ingredient in the form of a granulate, for example, in admixture with fillers such as corn starch, binders and/or glidants such as talc or magnesium stearate and optionally stabilizers. In soft capsules, the active ingredient is preferably dissolved or suspended in suitable liquids or wax-like substances such as fatty oils, paraffin oil or polyethylene glycols, it being possible also for stabilizers to be added.

Other forms of oral administration are, for example, syrups prepared in a customary manner that contain the active ingredient in, for example, suspended form and in a concentration of approximately from 5% to 20%, and preferably approximately 10%, or in a similar concentration that provides a suitable single dose when administered, for example, in measures of 5 or 10 ml. Also suitable are, for example, powdered or liquid concentrates for preparing shakes, for example, in milk. Such concentrates can also be packed in single-dose quantities.

Particularly suitable dosage forms for parenteral administration are sterile aqueous solutions of an active ingredient in water-soluble form, for example, a water-soluble salt, or sterile aqueous injection suspensions which contain substances increasing the viscosity, for example, sodium, carboxymethyl cellulose, sorbitol and/or dextran, and optionally stabilizers. In addition, the active ingredient, with or without adjuvants, can also be in lyophilized form and brought into solution prior to parenteral administration by the addition of suitable solvents.

The invention relates also to compositions for diagnostic purposes that contain a suitable metal complex of a compound of the formula in which R_1 has the above meanings, R_2 represents hydroxy and R_3 represents a group of the formula $-N(R_4, R_5)$ in which R_4 represents hydroxy and R_5 has the above meanings, preferably in the form of an aqueous solution or in the form of a dry preparation.

The invention relates also to a method of treatment of pathological conditions in a mammal, especially human, which as has been described hereinabove, are associated with an excess of a trivalent metal cation such as aluminum or, especially, iron (III), in the body, which method comprises administering, preferably orally, a prophylactically or therapeutically effective amount of a compound of the formula or of a pharmaceutically acceptable salt thereof. There are used for this purpose especially the above-mentioned pharmaceutical compositions, a daily dose of from approximately 100 mg to approximately 2,000 mg, and preferably from approximately 300 mg to approximately 1,000 mg, of a compound of the present invention being administered to a warm-blooded animal of approximately 70 kg body weight. The dosage can be administered orally in several, for example, three, individual doses. For systemic, e.g., subcutaneous, administration, the more water-soluble salt forms of the compounds of the formula, e.g., the sodium salt, are preferred, for example, orally, or alternatively, subcutaneously.

The following examples serve to illustrate the invention, but should not be construed as a limitation thereof. Temperatures are given in degrees Centigrade.

Preparation of Drugs. Drug solutions were prepared in 60% water, 40% Cremophor RH-40.

EXAMPLE 1**(S)-Desmethyldesferrithiocin, N-Methylhydroxamate (4)**

BOP (442.3 mg, 1.0 mmol) was added to a solution of 1 (224.2 mg, 1.0 mmol) and N-methylhydroxylamine hydrochloride (83.52 mg, 1.0 mmol) in DMF (8 ml) at 0°C. A solution of diisopropylethylamine (DIEA, 129.2 mg, 1.0 mmol) in DMF (2 ml) was added dropwise to the above solution at 0°C. The mixture was stirred at 0°C for 15 minutes and at room temperature overnight. Solvent was removed under high vacuum and the residue was treated with EtOAc (30 ml). The organic phase was washed with 10 ml portions of saturated NaHCO₃, saturated NaCl, 10% citric acid and saturated NaCl, and solvent was removed by rotary evaporation. Purification of the residue on a Sephadex LH-20 column, eluting with 3% EtOH/toluene, produced 120 mg (47%) of 4 as a yellow solid: $[\alpha]_D -41.3^\circ$ (c 2.34); NMR (CDCl₃/d₆DMSO) δ 3.27 (s, 3 H), 3.53 (dd, 2 H, J = 9, 6), 5.70 (t, 1 H, J = 9), 7.30 (d, 2 H, J = 3), 8.10 (t, 1 H, J = 3). Anal. (C₁₀H₁₁N₂O₃S) C, H, N.

EXAMPLE 2**(S)-Desmethyldesferrithiocin, N-[5-(Acetylhydroxyamino)-pentyl]hydroxamate (5)**

BOP (178.7 mg, 0.404 mmol) was added to a solution of 10 (86.0 mg, 0.404 mmol) and 1 (90.58 mg, 0.404 mmol) in DMF (8 ml) at 0°C. A solution of DIEA (52.2 mg, 0.404 mmol) in DMF (2 ml) was added dropwise to the cold solution. The mixture was stirred at 0°C for 15 minutes and at room tempera-

tur overnight. Solvent was removed under high vacuum, and the residue was treated with EtOAc (40 ml). Product was isolated and purified by the procedure of 4 to furnish 93 mg (60%) of 5 as an oil: $[\alpha]_D -16.7^\circ$ (c 9.85); NMR (CD_3OD) δ 1.30 - 1.90 (m, 6 H), 2.06 (s, 3 H), 3.40 - 3.80 (m, 6 H), 5.93 (t, 1 H, $J = 9$), 7.33 (d, 2 H, $J = 3$), 8.06 (t, 1 H, $J = 3$); HRMS calcd. $C_{16}H_{23}N_4O_5S$ 383.1389 [$M + 1$], $C_{16}H_{22}N_4O_5S$ [M], 382.1311, found 383.1406 [$M + 1$], 382.1344 [M].

EXAMPLE 3

2-(2'-Hydroxynaphth-1'-yl)- Δ^2 -thiazoline- (4R)-carboxylic Acid (4)

A mixture of 14 (10.11 g, 47.0 mmol) and L-cysteine (11.39 g, 94.0 mmol) in methanol (670 ml) was heated under reflux for 46 hours under nitrogen. The mixture was filtered and the filtrate concentrated. The residue was taken up in acetone (100 ml). The precipitated ammonium salt of 4 was filtered off, washed with acetone (100 ml) and then taken up in 0.5 N hydrochloric acid (200 ml). The mixture was extracted with ethyl acetate (3 x 150 ml). The organic layer was dried (Na_2SO_4) and concentrated, providing 3.86 g (30%) of 4 as yellow crystals, mp 150-151°C. IR (KBr): 1720 (C=O), 1615 (C=C), 1460 (C-H) cm^{-1} . 1H NMR ($DMSO-d_6$): δ 8.13 (d, 1 arom H), 7.92 (d, 1 arom H), 7.85 (d, 1 arom H), 7.50 (m, 1 arom H), 7.36 (m, 1 arom H), 7.23 (d, 1 arom H), 5.45 (dd, 1 CH), 3.82 (dd, 1/2 CH_2 , $J_{gem} = 12$ Hz, $J_{vic} = 9$ Hz), 3.73 (dd, 1/2 CH_2 , $J_{vic} = 8$ Hz). 1H NMR (CD_3OD): δ 8.25 (d, 1 H, $J = 9$ Hz),

7.78 - 7.87 (m, 2 H), 7.46 - 7.51 (m, 1 H), 7.32 - 7.36 (m, 1 H), 7.15 (d, 1 H, J = 9 Hz), 5.45 (dd, 1 H), 3.77 - 3.90 (m, 2 H). ¹³C NMR (CD₃OD): δ 173.9 (C=N)*, 173.6 (C=O)*, 157.8 (arom CO), 134.4 (arom CH), 133.4 (arom C), 129.7 (arom CH), 129.6 (arom C), 128.4 (arom CH), 124.6 (arom CH), 124.5 (arom CH), 119.7 (arom CH), 111.9 (arom C), 76.4 (CH), 36.3 (CH₂) (* = interchangeable). MS (CI, NH₃): m/z (%) = 274 [M + 1] (75), 187 (100). Anal. (C₁₄H₁₁NO₃S) C, H, N, S.

EXAMPLE 4

2-(2'-Hydroxynaphth-1'-yl)-Δ²-thiazoline- (4S)-carboxylic Acid (5)

Compound 5 was prepared from D-cysteine and 14 using the method of 4. The ¹H NMR (CD₃OD) of 5 is identical with that of 4. HRMS (FAB, m-nitrobenzyl alcohol): calcd. for C₁₄H₁₁NO₃S, 274.0538 [M + 1]. Anal. (C₁₄H₁₁NO₃S) C, H, N.

EXAMPLE 5

2-(3'-Hydroxynaphth-2'-yl)-Δ²-thiazoline- (4R)-carboxylic Acid (6)

A mixture of 20 (3.77 g, 22.3 mmol) and L-cysteine (5.40 g, 44.6 mmol) in methanol (133 ml) and 0.1 M phosphate buffer (pH 5.95, 66 ml) was stirred at 60°C for 5 hours under nitrogen. L-Cysteine (2.70 g, 22.3 mmol) was added and the mixture was stirred at 60°C for an additional 18 hours. After

concentration to about 70 ml, 2% KHCO_3 (156 ml) was added and the mixture was extracted with ether (3 x 100 ml). The aqueous layer was acidified to a pH of 3 with 1 N hydrochloric acid (75 ml) and extracted with ethyl acetate (3 x 150 ml).
5 The organic layer was dried (Na_2SO_4) and concentrated to furnish 5.34 g (88%) of 6 as yellow crystals, mp 226-227°C. IR (KBr): 3040 (O-H), 1710 (C=O), 1635 (C=C), 1230 (C-O) cm^{-1} . ^1H NMR ($\text{DMSO}-d_6$): δ 13.28 (s, 1 CO_2H), 12.15 (s, 1 OH), 8.20 (s, 1 arom H), 8.02 (d, 1 arom H), 7.78 (d, 1 arom H),
10 7.54 (dd, 1 arom H), 7.37 (s, 1 arom H), 7.36 (dd, 1 arom H), 5.57 (dd, 1 H), 3.80 (dd, 1/2 CH_2 , $J_{\text{gem}} = 12$ Hz, $J_{\text{vic}} = 9$ Hz), 3.71 (dd, 1/2 CH_2 , $J_{\text{vic}} = 8$ Hz). ^1H NMR (CD_3OD): δ 8.09 (s, 1 H), 7.84 (d, 1 H, $J = 8$ Hz), 7.69 (d, 1 H, $J = 8$ Hz), 7.45 - 7.50 (m, 1 H), 7.27 - 7.34 (m, 2 H), 5.49 (t, 1 H, $J = 9$ Hz),
15 3.74 (d, 2 H, $J = 8$ Hz). ^{13}C NMR ($\text{DMSO}-d_6$): δ 172.6 (C=N)*, 171.2 (C=O)*, 154.3 (arom CO), 135.9 (arom C), 132.1 (arom CH), 128.7 (arom CH), 117.9 (arom C), 110.6 (arom CH), 76.7 (CH), 33.5 (CH_2) (* = interchangeable). Anal. ($\text{C}_{14}\text{H}_{11}\text{NO}_3\text{S}$) C, H, N, S.

20

EXAMPLE 6

2-(3'-Hydroxynaphth-2'-yl)- Δ^2 -thiazoline-

(4S)-carboxylic Acid (7)

Compound 7 was prepared from α -cysteine and 20 using the method of 6. The ^1H NMR (CD_3OD) of 7 is identical with
25 that of 6. Anal. ($\text{C}_{14}\text{H}_{11}\text{NO}_3\text{S}$) C, H, N.

EXAMPLE 7**2-(Benzyloxy)-1-naphthaldehyde (9)**

A mixture of 8 (20.00 g, 116 mmol), K_2CO_3 (16.03 g, 116 mmol) and benzyl chloride (19.11 g, 151 mmol), 17.4 ml) in ethanol (200 ml) was heated under reflux for 39 hours. Water (200 ml) was added and the mixture was extracted with CH_2Cl_2 (1 x 200 ml, 2 x 100 ml). The organic layer was dried ($MgSO_4$) and concentrated. The residue was crystallized from 10:1 cyclohexane/ethyl acetate (400 ml), giving 22.14 g (73%) of 9 as yellow crystals, mp 123-124°C (lit. mp 120-121°C).

EXAMPLE 8**2-(Benzyloxy)-1-naphthoic Acid (10)**

Sulfamic acid (17.28 g, 178 mmol) was added to a solution of 9 (21.11 g, 80.5 mmol) in acetone (420 ml) and water (210 ml) at 0°C. Over a period of 20 minutes, 80% $NaClO_2$ (10.42 g, 92.2 mmol) was added at 0°C. The solution was stirred at 0°C for 30 minutes and then concentrated to about 200 ml. After dilution with water (200 ml), the mixture was extracted with CH_2Cl_2 (1 x 200 ml, 2 x 100 ml). The organic layer was dried ($MgSO_4$) and concentrated. Crystallization from cyclohexane/ethyl acetate (1:1) generated 19.12 g (85%) of 10 as pale yellow crystals, mp 127-128°C (lit. mp 128-130°C).

EXAMPLE 9**2-(Benzyloxy)-1-naphthamide (12)**

Oxalyl chloride (25.9 ml, 137 mmol) was added to a mixture of 10 (19.12 g, 68.7 mmol) and DMF (4.34 ml) in dry toluene (325 ml). The solution was stirred at room temperature for 1 hour. The toluene phase was separated from the DMF phase and concentrated. The residue was taken up in toluene (300 ml) and concentrated again, affording 20.21 g (99%) of 11 as yellow crystals, which were dissolved in CH_2Cl_2 (300 ml) and added dropwise to a mixture of concentrated NH_4OH (200 ml) and CH_2Cl_2 (120 ml). The mixture was vigorously stirred at room temperature for 24 hours. Water (200 ml) was added, the phases were separated and the aqueous layer was extracted with ethyl acetate (3 x 200 ml). The combined organic layers were dried (MgSO_4) and concentrated. Crystallization from CH_2Cl_2 gave 16.00 g (85%) of 12 as colorless crystals, mp 153-154°C. IR (KBr): 3400 (N-H), 3180 (N-H), 1510 (C=C) cm^{-1} . ^1H NMR δ 8.11 (d, 1 arom H), 7.85 (d, 1 arom H), 7.78 (d, 1 arom H), 7.54 - 7.26 (8 arom H), 6.18 (s, 1 NH), 6.09 (s, 1 NH), 5.26 (s, 1 CH_2). Anal. ($\text{C}_{18}\text{H}_{15}\text{NO}_2$) C, H, N.

EXAMPLE 10**Ethyl 2-(Benzyloxy)-1-naphthimide (13)**

Triethyloxonium hexafluorophosphate (19.20 g, 58.1 mmol) was added to a solution of 12 (16.00 g, 57.7 mmol) in CH_2Cl_2 (710 ml). The solution was stirred at room temperature for 24 hours and then poured into ice-cold 0.5 M K_2CO_3 (700

ml). The phases were separated and the aqueous layer was extracted with CH_2Cl_2 (2 x 100 ml). The organic layers were dried and concentrated. Chromatography with CH_2Cl_2 as the eluant gave 15.21 g (86%) of 13 as colorless crystals, mp 55-56°C. IR (KBr): 3325 (N-H), 2975 (C-H), 1640 (C=C) cm^{-1} . ^1H NMR: δ 7.80 - 7.72 (3 arom H), 7.50 - 7.21 (8 arom H), 6.77 (s, 1 NH), 5.20 (s, 1 CH_2), 4.48 (q, 1 CH_2 , $J = 7$ Hz), 1.40 (t, 1 CH_3). Anal. ($\text{C}_{20}\text{H}_{19}\text{NO}_2$) C, H, N.

EXAMPLE 11

Ethyl 2-Hydroxy-1-naphthimide (14)

Palladium on carbon (10%, 2.57 g) was introduced into a solution of 13 (15.21 g, 49.8 mmol) in ethanol (430 ml). The suspension was stirred under a hydrogen atmosphere for 6 hours. After filtration through Celite, the filtrate was concentrated, giving 10.11 g (94%) of 14 as yellow crystals, mp 145-146°C. IR (KBr): 2980 (C-H), 1620 (C=C), 1085 (C-O) cm^{-1} . ^1H NMR: δ 8.65 (d, 1 arom H), 7.76 (d, 1 arom H), 7.71 (d, 1 arom H), 7.47 (m, 1 arom H), 7.29 (m, 1 arom H), 7.15 (d, 1 arom H), 4.29 (q, 1 CH_2 , $J = 7$ Hz), 1.42 (t, 1 CH_3). Anal. ($\text{C}_{13}\text{H}_{13}\text{NO}_2$) C, H, N.

EXAMPLE 12

3-Acetoxy-2-naphthoic Acid (16)

Concentrated sulfuric acid (8 drops) was added to a refluxing mixture of 15 (40.00 g, 213 mmol) in acetic anhydride (38 ml, 426 mmol). The mixture was maintained at

reflux for 5 minutes. After cooling to room temperature, the solid was filtered off, washed with acetic acid and ethanol and dried under high vacuum to yield 40.31 g (82%) of 16 as pale yellow crystals, mp 185-186°C (lit. mp 184-186°C).

5

EXAMPLE 13

3-Hydroxy-2-naphthamide (18)

Oxalyl chloride (65 ml, 350 mmol) was added dropwise to a solution of 16 (40.31 g, 175 mmol) in DMF (17.2 ml) and dry toluene (850 ml). The mixture was stirred at room temperature for 1 hour. The toluene layer was separated from DMF and concentrated. The residue was taken up in toluene (500 ml) and concentrated again, providing 42.02 g (97%) of 17 as yellow crystals, which were dissolved in CH_2Cl_2 (500 ml) and added dropwise to a mixture of concentrated NH_4OH (420 ml) and CH_2Cl_2 (250 ml). The mixture was vigorously stirred at room temperature for 24 hours and then acidified to a pH of 3 with 9% HCl (1.60 L). Precipitate was filtered off, washed with water (4 x 150 ml) and dried under high vacuum, providing 29.95 g (95%) of 18 as yellow crystals, mp 216-217°C (lit. mp 217-218°C).

15

20

EXAMPLE 14

3-Acetoxy-2-naphthamide (19)

Acetic anhydride (19.2 ml, 200 mmol) was added to a solution of 18 (29.95 g, 160 mmol) in pyridine (32 ml, 400 mmol) and the mixture was maintained at room temperature for

25

30 minutes. The solid was filtered off, washed with acetone and dried (MgSO_4), generating 27.06 g (74%) of 19 as pale yellow crystals, mp 201-202°C (lit. 203-205°C).




EXAMPLE 15


5 3-Hydroxy-2-naphthonitrile (20)

A mixture of 19 (4.96 g, 21.6 mmol) and thionyl chloride (6.32 ml, 86.4 mmol) was heated under reflux for 2 hours. The solution was concentrated in vacuo to dryness. The residue was taken up in water (10 ml), methanol (200 ml)
10 and 1 N NaOH solution (75 ml). The solution was stirred at room temperature for 19 hours and concentrated. Chromatography, eluting with 1:1 cyclohexane/ethyl acetate, provided 2.41 g (66%) of 20 as yellow crystals, mp 188-189°C (lit. mp 188-189°C).


"THIAZOLINE ACID DERIVATIVES"**I CLAIM:**

1. A compound of the formula:






(IV),



(V),



(VI),

wherein: R may be H or acyl;

R_1, R_2, R_3, R_4 and R_7 may be the same or different and represent H, alkyl or hydrocarbyl arylalkyl having up to 14 carbon atoms, or $-\text{CH}_2[\text{O}-(\text{CH}_2)_x]_y\text{OCH}_3$, wherein x is 1-10 and y is 0-10;

R_5 is H, alkyl having up to 15 carbon atoms, $-\text{CH}_2)_{1,2}[\text{O}-(\text{CH}_2)_x]_y\text{OCH}_3$, wherein x is 1-10 and y is

0-10, or $-\text{CH}_2)_z-\text{N}-\overset{\text{O}}{\parallel}{\text{C}}-\left[(\text{CH}_2)_z-\text{N}-\overset{\text{O}}{\parallel}{\text{C}}-\text{R}_1\right]_q$, wherein R_1 is as

defined above, z is 1-10 and q is 0-5;

R_6 is H or acyl;

n is 0-10;

a salt thereof with a pharmaceutically acceptable acid, or a pharmaceutically acceptable complex thereof.

1 2. A compound according to claim 1 having the
2 formula I wherein $R = R_1 = R_2 = R_3 = R_4 = R_6 = \text{H}$; R_5 is methyl
3 and $n = 0$.

1 3. A compound according to claim 1 having the
2 formula I wherein $R = R_1 = R_2 = R_3 = R_4 = R_5 = R_6 = \text{H}$ and $n = 0$.

1 4. A compound according to claim 1 having the
2 formula III wherein $R = R_1 = R_2 = R_3 = R_4 = R_6 = H$; R_5 is methyl
3 and $n = 0$.

1 5. A compound according to claim 1 having the
2 formula III wherein $R = R_1 = R_2 = R_3 = R_4 = R_5 = R_6 = H$ and
3 $n = 0$.

1 6. A compound according to claim 1 having the
2 formula V wherein $R = R_1 = R_2 = R_3 = R_4 = R_6 = H$; R_5 is methyl
3 and $n = 0$.

1 7. A compound according to claim 1 having the
2 formula V wherein $R = R_1 = R_2 = R_3 = R_4 = R_5 = R_6 = H$ and $n = 0$.


1 8. An optically pure compound according to claim
2 1.

1 9. A pharmaceutical composition in unit dosage
2 form comprising a therapeutically effective amount of a com-
3 pound according to claim 1 and a pharmaceutically acceptable
4 carrier therefor.


1 10. A method of preventing or treating a patho-
2 logical condition in a human or non-human animal that is
3 associated with an excess of a trivalent metal, ion or com-
4 pound thereof comprising administering to said animal a

5 therapeutically effective amount of a compound according to
 6 claim 1.


11. A compound of the formulae:






(VII),



(VIII),



(IX),



wherein: R may be H or acyl;

R_1, R_2, R_3, R_4 and R_7 may be the same or different and represent H, alkyl or hydrocarbyl arylalkyl having up to 14 carbon atoms, or $-\text{CH}_2\left[\text{O}-(\text{CH}_2)_x\right]_y\text{OCH}_3$;

x is 1-10; and

y is 0-10;

or a pharmaceutically acceptable salt or complex thereof.

1 12. A compound according to claim 11 having the
2 formula VII wherein $R = R_1 = R_2 = R_3 = R_4 = \text{H}$ and $x = 0-15$.

1 13. A compound according to claim 11 having the
2 formula VIII wherein $R = R_1 = R_2 = R_3 = R_4 = \text{H}$ and $x = 0-15$.

1 14. A compound according to claim 11 having the
2 formula IX wherein $R = R_1 = R_2 = R_3 = R_4 = R_7 = \text{H}$ and $y = 0$.

1 15. A compound according to claim 11 having the
2 formula X wherein $R = R_1 = R_2 = R_3 = R_4 = R_7 = \text{H}$ and $y = 0$.

1 16. A compound according to claim 11 having the
2 formula XI wherein $R = R_1 = R_2 = R_3 = R_4 = R_7 = \text{H}$ and $y = 0$.

1 17. A compound according to claim 11 having the
2 formula XII wh rein $R = R_1 = R_2 = R_3 = R_4 = R_7 = H$ and $y = 0$.

1 18. An optically pure compound according to claim
2 11.

1 19. A pharmaceutical composition in unit dosage form
2 comprising a therapeutically effective amount of a compound of
3 claim 11 and a pharmaceutically acceptable carrier therefor.

1 20. A method of preventing or treating a patho-
2 logical condition in a human or non-human animal that is asso-
3 ciated with an excess of a trivalent metal, ion or compound
4 thereof comprising administering to said animal a therapeutic-
5 ally effective amount of a compound of claim 11.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/04666

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07D 277/10; A61K 31/425

US CL :548/204; 546/280; 514/365

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 548/204; 546/280; 514/365

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BERGERON ET AL., The Desferrithiocin Pharmrcophore. [J. MED. CHEM. 1994, Vol. 37, 1411-1417, see entire document.	1-3, 8-10



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combinations being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

23 MAY 1997

Date of mailing of the international search report

25 JUL 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ROBERT GERSTL, ac

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/04666

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/04666

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate search fees must be paid.

Group I, claims 1-10, drawn to Amides.

Group II, claims 11-20, drawn to Acids.

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The compounds of Group II are starting materials for Group I.